Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Zhihua Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2003-5457; OpenAlex author ID A5100319843. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
71
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 4 papers

Papers 22

  1. Cancer-associated fibroblasts drive gemcitabine resistance in pancreatic cancer by promoting ferroptosis resistance via the PAX6/PAK3/SLC3A2 axis. Co-author DOI 10.1016/j.canlet.2026.218381↗
  2. NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. Co-author DOI 10.1038/s41467-026-68409-0↗
  3. Correction: circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Co-author DOI 10.1186/s12943-026-02730-6↗
  4. Lactylation-driven NSUN2-mediated RNA m5C modification promotes perineural invasion in pancreatic cancer. Co-author DOI 10.7150/thno.122294↗
  5. Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancrea… Co-author DOI 10.1186/s12916-025-04234-4↗
  6. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma… Co-author DOI 10.1038/s41392-024-01948-4↗
  7. Corrigendum to "Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer" [Canc. Lett. 459(2019)204-215]. Co-author DOI 10.1016/j.canlet.2022.215897↗
  8. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Co-author DOI 10.1186/s12943-022-01501-3↗
  9. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway. Co-author DOI 10.1186/s13046-021-02237-6↗
  10. Correction: Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-021-03420-5↗
  11. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis. Co-author DOI 10.1186/s12943-020-01196-4↗
  12. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Co-author DOI 10.1186/s12943-020-01205-6↗
  13. Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.06.005↗
  14. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practic… Co-author DOI 10.3748/wjg.v25.i1.138↗
  15. FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-017-0052-1↗
  16. Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0486-0↗
  17. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-018-1104-x↗
  18. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jcmm.13202↗
  19. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1097/md.0000000000001345↗
  20. Metabolic phenotypes in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0115153↗
  21. Green tea consumption and risk of pancreatic cancer: a meta-analysis. First author DOI 10.3390/nu6114640↗
  22. Gastrectomy and risk of pancreatic cancer: systematic review and meta-analysis of observational studies. Last author DOI 10.1007/s10552-012-0005-z↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangyou Zheng · 11 shared papers, 2017–2026 · strength 1.47
  2. Quanbo Zhou · 10 shared papers, 2012–2022 · strength 0.90
  3. Changhao Chen · 7 shared papers, 2015–2026 · strength 0.83
  4. Rufu Chen · 6 shared papers, 2015–2026 · strength 0.81
  5. Chonghui Hu · 5 shared papers, 2019–2026 · strength 0.76
  6. Zhiqiang Fu · 7 shared papers, 2015–2026 · strength 0.74
  7. Guolin Li · 7 shared papers, 2018–2022 · strength 0.71
  8. Lusheng Wei · 7 shared papers, 2017–2022 · strength 0.63
  9. Huilin Ye · 7 shared papers, 2017–2022 · strength 0.63
  10. Yimin Liu · 7 shared papers, 2015–2021 · strength 0.56
  11. Huimou Chen · 2 shared papers, 2026 · strength 0.55
  12. Rufu Chen · 6 shared papers, 2012–2022 · strength 0.50
  13. Xiaofeng Guo · 3 shared papers, 2020–2026 · strength 0.50
  14. Yao Kong · 3 shared papers, 2020–2026 · strength 0.50
  15. Yuming Luo · 3 shared papers, 2020–2026 · strength 0.50
  16. Rihua He · 2 shared papers, 2022–2026 · strength 0.39
  17. Chuntao Gao · 2 shared papers, 2025–2026 · strength 0.38
  18. Rufu Chen · 3 shared papers, 2020–2022 · strength 0.36
  19. Tao Xia · 2 shared papers, 2024–2025 · strength 0.33
  20. Deliang Fu · 2 shared papers, 2024–2025 · strength 0.33
  21. Renpeng Xia · 2 shared papers, 2022 · strength 0.30
  22. Y P. Li · 1 shared paper, 2026 · strength 0.29
  23. Tianhao Huang · 1 shared paper, 2026 · strength 0.24
  24. Yu Zhou · 1 shared paper, 2026 · strength 0.24
  25. Rufu Chen · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.